AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- -$1K to -$15K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 2 cutMore adding
Key stats
Fundamentals Sep 30- Open
- $254.86
- 52-wk high
- $495.55
- High
- $257.27
- 52-wk low
- $197.81
- Low
- $251.02
- Prev close
- $255.36
- Mkt cap
- $34.00B
- P/E
- 44.4x
- Volume
- 754.3K
- Fwd P/E
- 19.7x
- Beta
- 0.30
- P/S
- 7.1x
- P/B
- 24.9x
- Profit margin
- +16.1%
- Op margin
- +17.9%
- ROE
- +96.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ALNY filings
Are insiders buying or selling Alnylam Pharmaceuticals Inc (ALNY) stock?
Neither. Alnylam Pharmaceuticals Inc (ALNY) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded ALNY recently?
Sen. Cory A Booker (D) sold $1K to $15K on Aug 11, 2026, disclosed 29 days later. In total, 1 member disclosed 1 ALNY trade with trade dates in the last 180 days, filed a median 29 days after trading.
How current is this ALNY smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- CI
Citadel
$49.8M
added
- SU
Susquehanna
$31.0M
added
- BA
Balyasny
$26.9M
bought
What insiders are doing
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in ALNY right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 16.0% below what analysts expected.
Earnings per share
$1.44 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
FY 2026 guidance
$4.70B to $5.10B
No comparable estimate
Reports Oct 29, 2026, in 28 days
Estimates as of Oct 1, 2026
EPS expected
$1.94 to $3.45
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.25B | $1.10B | $1.17B | $1.29B |
| Cost of what it sold | $197.2M | $267.7M | $211.1M | $298.3M |
| Gross profit | $1.05B | $829.3M | $956.1M | $992.7M |
| What it spent | ||||
| Research and development | $358.8M | $372.2M | $364.9M | $413.1M |
| Sales and admin | $322.1M | $325.4M | $322.6M | $347.9M |
| Total operating expenses | $683.8M | $697.6M | $687.4M | $761.2M |
| What was left | ||||
| Operating profit | $368.0M | $131.7M | $268.6M | $231.4M |
| Interest on debt | $44.4M | $129.3M | $69.3M | $82.1M |
| Profit before tax | $239.0M | $161.1M | $221.7M | $177.8M |
| Tax | -$12.1M | -$25.3M | -$15.7M | $13.3M |
| Net profit | $251.1M | $186.4M | $206.0M | $164.5M |
| EBITDA | $297.2M | $304.0M | $304.5M | $244.7M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
BullishSep 28Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com
NeutralSep 27Form 4 Alnylam Pharmaceuticals Inc For: 27 September
NeutralSep 27Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO
Leans bullishSep 26H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455
BullishSep 21Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Leans bullishSep 20Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
BullishSep 20
Macro
20 macro signals shaping ALNY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results